Table 3. Correlation of CXCL1/CXCL2/CXCL8 with tumor features.
| Items | CXCL1 | CXCL2 | CXCL8 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High | P | Low | High | P | Low | High | P | |||
| Differentiation, No. (%) | 0.126 | 0.638 | 0.064 | ||||||||
| Well | 22 (18.8) | 12 (10.4) | 18 (16.8) | 16 (12.8) | 18 (19.4) | 16 (11.5) | |||||
| Moderate | 67 (57.3) | 70 (60.9) | 61 (57.0) | 76 (60.8) | 55 (59.1) | 82 (59.0) | |||||
| Poor | 28 (23.9) | 33 (28.7) | 28 (26.2) | 33 (26.4) | 20 (21.5) | 41 (29.5) | |||||
| Tumor size, No. (%) | 0.295 | 0.423 | 0.219 | ||||||||
| ≤5 cm | 75 (64.1) | 66 (57.4) | 68 (63.6) | 73 (58.4) | 61 (65.6) | 80 (57.6) | |||||
| >5 cm | 42 (35.9) | 49 (42.6) | 39 (36.4) | 52 (41.6) | 32 (34.4) | 59 (42.4) | |||||
| LYN metastasis, No. (%) | 0.002 | 0.039 | 0.005 | ||||||||
| No | 84 (71.8) | 60 (52.2) | 74 (69.2) | 70 (56.0) | 68 (73.1) | 76 (54.7) | |||||
| Yes | 33 (28.2) | 55 (47.8) | 33 (30.8) | 55 (44.0) | 25 (26.9) | 63 (45.3) | |||||
| TNM stage, No. (%) | 0.010 | 0.008 | 0.004 | ||||||||
| I | 47 (40.2) | 29 (25.2) | 45 (42.0) | 31 (24.8) | 39 (41.9) | 37 (26.6) | |||||
| II | 33 (28.2) | 34 (29.6) | 28 (26.2) | 39 (31.2) | 28 (30.1) | 39 (28.1) | |||||
| III | 37 (31.6) | 52 (45.2) | 34 (31.8) | 55 (44.0) | 26 (28.0) | 63 (45.3) | |||||
| CEA level, No. (%) | 0.275 | 0.827 | 0.180 | ||||||||
| Normal* | 52 (44.4) | 43 (37.4) | 43 (40.2) | 52 (41.6) | 43 (46.2) | 52 (37.4) | |||||
| Abnormal* | 65 (55.6) | 72 (62.6) | 64 (59.8) | 73 (58.4) | 50 (53.8) | 87 (62.6) | |||||
*, normal CEA level ≤5 ng/mL and abnormal CEA level >5 ng/mL. CXCL, chemokine (C-X-C motif) ligand; LYN, lymph node; CEA, carcinoembryonic antigen.